The company's collaboration partner, Vertex Pharmaceuticals(NASDAQ: VRTX), made progress activating authorized treatment centers capable of administrating Casgevy, but CRISPR still hasn't reported any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback